Use of motion tracking in stereotactic body radiotherapy: Evaluation of uncertainty in off-target dose distribution and optimization strategies

Authors

  • F. Casamassima Dipartimento di Fisiopatologia Clinica, Università di Firenze, Piazza indipendenza 11, 50129, Firenze, Italy
  • C. Cavedon Servizio di Fisica Sanitaria, Ospedale S.Bortolo, ULSS 6, Vicenza, Italy
  • P. Francescon Servizio di Fisica Sanitaria, Ospedale S.Bortolo, ULSS 6, Vicenza, Italy
  • J. Stancanello Servizio di Fisica Sanitaria, Ospedale S.Bortolo, ULSS 6, Vicenza, Italy
  • M. Avanzo Servizio di Fisica Sanitaria, Ospedale S.Bortolo, ULSS 6, Vicenza, Italy
  • S. Cora Servizio di Fisica Sanitaria, Ospedale S.Bortolo, ULSS 6, Vicenza, Italy
  • P. Scalchi Servizio di Fisica Sanitaria, Ospedale S.Bortolo, ULSS 6, Vicenza, Italy

DOI:

https://doi.org/10.1080/02841860600908962

Abstract

Spatial accuracy in extracranial radiosurgery is affected by organ motion. Motion tracking systems may be able to avoid PTV enlargement while preserving treatment times, however special attention is needed when fiducial markers are used to identify the target can move with respect to organs at risk (OARs). Ten patients treated by means of the Synchrony system were taken into account. Sparing of irradiated volume and of complication probability were estimated by calculating treatment plans with a motion tracking system (Cyberknife Synchrony, Sunnyvale, CA, USA) and a PTV-enlargement strategy for ten patients. Six patients were also evaluated for possible inaccuracy of estimation of dose to OARs due to relative movement between PTV and OAR during respiration. Dose volume histograms (DVH) and Equivalent Uniform Dose (EUD) were calculated for the organs at risk. In the cases for which the target moved closer to the OAR (three cases of six), a small but significant increase was detected in the DVH and EUD of the OAR. In three other cases no significant variation was detected. Mean reduction in PTV volume was 38% for liver cases, 44% for lung cases and 8.5% for pancreas cases. NTCP for liver reduced from 23.1 to 14.5% on average, for lung it reduced from 2.5 to 0.1% on average. Significant uncertainty may arise from the use of a motion-tracking device in determination of dose to organs at risk due to the relative motion between PTV and OAR. However, it is possible to limit this uncertainty. The breathing phase in which the OAR is closer to the PTV should be selected for planning. A full understanding of the dose distribution would only be possible by means of a complete 4D-CT representation.

Downloads

Download data is not yet available.

Downloads

Published

2006-01-01

How to Cite

Casamassima, F., Cavedon, C., Francescon, P., Stancanello, J., Avanzo, M., Cora, S., & Scalchi, P. (2006). Use of motion tracking in stereotactic body radiotherapy: Evaluation of uncertainty in off-target dose distribution and optimization strategies. Acta Oncologica, 45(7), 943–947. https://doi.org/10.1080/02841860600908962